Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/vdsadmin/www/web-pharmacy-review.com/engine/classes/templates.class.php on line 77 Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/vdsadmin/www/web-pharmacy-review.com/engine/classes/templates.class.php on line 159 Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/vdsadmin/www/web-pharmacy-review.com/engine/classes/templates.class.php on line 163 O » Drugs and Pharmaceuticals Index

1. Name Of The Medicinal Product

OCTIM® Nasal Spray

2. Qualitative And Quantitative Composition

Desmopressin acetate 150 micrograms per actuation

For excipients, see 6.1

3. Pharmaceutical Form

Nasal Spray, Solution

Clear, colourless solution

4. Clinical Particulars

4.1 Therapeutic Indications

OCTIM Nasal Spray is indicated as follows:

1) To increase Factor VIIIC and Factor VIII:Ag (vWf) in patients with mild to moderate haemophilia or von Willebrand's disease undergoing surgery, following trauma or with other bleeding episodes such as menorrhagia and epistaxis.

2) To test for fibrinolytic response.

4.2 Posology And Method Of Administration

Mild to moderate haemophilia and von Willebrand's disease:

Adults (including the elderly) should take 300 micrograms (one spray into each nostril) half an hour before surgery or at bleeding.

Under direct medical supervision, further doses may be administered at 12 hourly intervals so long as cover is required. As some patients have shown a diminishing response to successive doses, Factor VIII levels should continue to be monitored.

Unless specifically directed by the doctor, when OCTIM Nasal Spray is self-administered by the patient, there should be an interval of at least three days between doses.

Increase of Factor VIII levels are dependent on basal levels and are normally between 2 and 5 times the pre-treatment levels. If results from a previous administration of desmopressin are not available then blood should be taken pre-dose and 60 minutes post-dose for assay of Factor VIII levels in order to monitor response.

1. Name Of The Medicinal Product

Oxaliplatin Hospira 5 mg/ml Powder for Solution for Infusion

2. Qualitative And Quantitative Composition

One ml of reconstituted solution contains oxaliplatin 5 mg.

50 mg vial: each vial contains 50 mg oxaliplatin for reconstitution in 10 ml of solvent.

100 mg vial: each vial contains 100 mg oxaliplatin for reconstitution in 20 ml of solvent.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Powder for solution for infusion.

A white to off-white powder

4. Clinical Particulars

4.1 Therapeutic Indications

Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:

• Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumour

• Treatment of metastatic colorectal cancer.

4.2 Posology And Method Of Administration

The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicinal product used, in conditions that guarantee the integrity of the medicinal product, the protection of the environment and in particular the protection of the personnel handling the medicinal products, in accordance with hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area.

Posology

FOR ADULTS ONLY

The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m? intravenously repeated every 2 weeks for 12 cycles (6 months).

The recommended dose for oxaliplatin in treatment of metastatic colorectal canc

1. Name Of The Medicinal Product

Optrex Infected Eye Drops

2. Qualitative And Quantitative Composition

Chloramphenicol 0.5% w/v.

For excipients, see 6.1.

3. Pharmaceutical Form

Eye drops, solution. A clear, slightly yellow solution.

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment of acute bacterial conjunctivitis.

4.2 Posology And Method Of Administration

One drop instilled into the infected eye every 2 hours for the first 48 hours and 4 hourly thereafter. To be used during waking hours only. The course of treatment is 5 days.

Treatment should continue for 5 days even if symptoms improve.

For ocular use.

4.3 Contraindications

Chloramphenicol eye drops must not be administered to:

• Patients who have a history of hypersensitivity to chloramphenicol or to any other ingredient of the drops.

• Patients who have experienced myelosuppression during previous exposure to chloramphenicol.

• Patients with a family history of blood dyscrasias.

4.4 Special Warnings And Precautions For Use

Chloramphenicol is absorbed systemically from the eye and systemic toxicity has been reported (see section 4.8).

In severe bacterial conjunctivitis and in cases where infection is not confined to the conjunctivae, the topical use of chloramphenicol should be supplemented by appropriate systemic treatment. Therefore, the patient should be referred to seek medical advice.

The use of topical chloramphenicol may occasionally result in overgrowth of non-susceptible organisms including fungi. If any new infection appears during treatment, the patient should be re

1. Name Of The Medicinal Product

2. Qualitative And Quantitative Composition

Onbrez Breezhaler 150 microgram inhalation powder, hard capsules:

Each capsule contains indacaterol maleate equivalent to 150 microgram indacaterol.

The delivered dose leaving the mouthpiece of the Onbrez Breezhaler inhaler is indacaterol maleate equivalent to 120 microgram indacaterol.

Excipients:

Each capsule contains 24.8 mg lactose.

Onbrez Breezhaler 300 microgram inhalation powder, hard capsules:

Each capsule contains indacaterol maleate equivalent to 300 microgram indacaterol.

The delivered dose leaving the mouthpiece of the Onbrez Breezhaler inhaler is indacaterol maleate equivalent to 240 microgram indacaterol.

Excipients:

Each capsule contains 24.6 mg lactose.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Inhalation powder, hard capsule

Onbrez Breezhaler 150 microgram inhalation powder, hard capsules:

Clear colourless capsules containing a white powder, with “IDL 150” printed in black above and company logo (

Onbrez Breezhaler 300 microgram inhalation powder, hard capsules:

Clear colourless capsules containing a white powder, with “IDL 300” printed in blue above and company logo (

4. Clinical Particulars

4.1 Therapeutic Indications

Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chron

Oxaliplatin 5mg/ml powder for solution for infusion

  • Read all of this leaflet carefully before you start using this medicine.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

In this leaflet:

  • 1. What Oxaliplatin is and what it is used for
  • 2. Before you use Oxaliplatin
  • 3. How to use Oxaliplatin
  • 4. Possible side effects
  • 5. How to store Oxaliplatin
  • 6. Further information

What Oxaliplatin Is And What It Is Used For

Oxaliplatin is used to treat metastatic (advanced) cancer of the colon (large bowel) or rectum (back passage), or as additional treatment following surgery to remove a tumour (growth) in the colon.

It is used in combination with other anticancer agents, 5-fluorouracil (5-FU) and folinic acid (FS).

Before You Use Oxaliplatin

Do not use Oxaliplatin

  • if you are allergic (hypersensitive) to oxaliplatin or the other ingredient of Oxaliplatin, lactose monohydrate.
  • if you are breast-feeding
  • if you already have a reduced number of blood cells (white blood cells and/or platelets).
  • if you already have tingling and numbness in the fingers and/or toes, and have difficulty pe

1. Name Of The Medicinal Product

Ovestin 1 mg cream

2. Qualitative And Quantitative Composition

1mg estriol in 1g cream

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Vaginal cream

Homogeneous, smooth, white to nearly white mass of creamy consistency.

4. Clinical Particulars

4.1 Therapeutic Indications

Hormone replacement therapy (HRT) for treatment of atrophic vaginitis (due to estrogen deficiency) in peri- and post-menopausal women.

As pre-surgery therapy for vaginal operations and during subsequent convalescence.

4.2 Posology And Method Of Administration

Ovestin cream is an estrogen-only product for intravaginal use.

One applicator-dose (applicator filled to the red mark) is 0.5g Ovestin cream containing 0.5 mg estriol.

Adults and Elderly

• Treatment of atrophic vaginitis

For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.

The usual dose for atrophic vaginitis associated with the menopause is one applicator-dose per day for 2 to 3 weeks.

As maintenance dosage, one applicator-dose twice a week is recommended.

Medication should be discontinued every 2 to 3 months for a period of 4 weeks to assess the necessity for further treatment.

• Pre-surgery therapy

One applicator-dose per day should begin 2 weeks before the operation.

• Post-surgery therapy

Following surgery a period of at least 2 weeks should be allowed before resuming therapy using one applicato

OCUFEN Eye drops, solution

Flurbiprofen sodium 0.03% w/v

Read all of this leaflet carefully before you start using this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

  • 1. What OCUFEN is and what it is used for
  • 2. Before you use OCUFEN
  • 3. How to use OCUFEN
  • 4. Possible side effects
  • 5. How to store OCUFEN
  • 6. Further information

What OCUFEN is and what it is used for

OCUFEN is used for two different purposes:

  • Given before and after eye surgery and laser surgery, to control eye inflammation in patients who have been recommended not to use steroids.
  • Given before an operation to help prevent the pupil becoming smaller during surgery.

OCUFEN belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs).

Before you use OCUFEN

Do not use OCUFEN

  • If you are allergic (hypersensitive) to:
    flurbiprofen (or other similar medicines)
    aspirin
    other ingredients listed in section 6
  • If you have a vir

1. Name Of The Medicinal Product

Olanzapine Sandoz 7.5 mg Film-coated Tablets

2. Qualitative And Quantitative Composition

Each film-coated tablet contains 7.5 mg olanzapine.

Excipient: 222.33 mg lactose/film-coated tablet

For a full list of excipients, see section 6.1

3. Pharmaceutical Form

Film-coated tablet

White, round (9 mm diameter).

4. Clinical Particulars

4.1 Therapeutic Indications

Adults

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1).

4.2 Posology And Method Of Administration

Adults

Schizophrenia: The recommended starting dose for olanzapine is 10 mg/day.

Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1).

Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day. For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation

1. Name Of The Medicinal Product

Oruvail IM Injection

2. Qualitative And Quantitative Composition

In terms of the active ingredient

Ketoprofen BP 100mg in 2 ml.

3. Pharmaceutical Form

Solution for IM injection

4. Clinical Particulars

4.1 Therapeutic Indications

Oruvail injection is recommended in the management of acute exacerbations of:

• Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis.

• Periarticular conditions such as fibrositis, bursitis, capsulitis, tendinitis and tenosynovitis.

• Low back pain of musculoskeletal origin and sciatica.

• Other painful musculoskeletal conditions.

• Acute gout.

• Control of pain and inflammation following orthopaedic surgery.

4.2 Posology And Method Of Administration

Adults: 50 to 100 mg every four hours, repeated up to a maximum of 200 mg in twenty-four hours. Following a satisfactory response, oral therapy should be instituted with ketoprofen capsules. It is recommended that the injection should not normally be continued for longer than three days.

Elderly: The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.

Paediatric dosage: not established.

Oruvail IM Injection is for intramuscular injection only.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4

4.3 Contraindications

1. Name Of The Medicinal Product

Oxaliplatin Hospira 5 mg/ml Concentrate for Solution for Infusion

2. Qualitative And Quantitative Composition

One ml of concentrate for solution for infusion contains 5 mg oxaliplatin.

10 ml of concentrate for solution for infusion contains 50 mg of oxaliplatin.

20 ml of concentrate for solution for infusion contains 100 mg of oxaliplatin.

40 ml of concentrate for solution for infusion contains 200 mg of oxaliplatin.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Concentrate for solution for infusion.

Clear, colourless solution.

4. Clinical Particulars

4.1 Therapeutic Indications

Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:

• Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumour

• Treatment of metastatic colorectal cancer.

4.2 Posology And Method Of Administration

The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicinal product used, in conditions that guarantee the integrity of the medicinal product, the protection of the environment and in particular the protection of the personnel handling the medicinal products, in accordance with hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area (see section 6.6).

Posology

FOR ADULTS ONLY

The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m? intravenously repeated every 2 weeks for 12

1. Name Of The Medicinal Product

Omnitrope 3.3 mg/ml solution for injection

2. Qualitative And Quantitative Composition

Somatropin* 3.3 mg (corresponding to 10 IU)/ ml.

One cartridge contains 1.5 ml corresponding to 5 mg Somatropin* (15 IU).

* produced in Escherichia coli by recombinant DNA technology.

Excipients:

One ml contains 9 mg benzyl alcohol.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Solution for injection

The solution is clear and colourless.

4. Clinical Particulars

4.1 Therapeutic Indications

Infants, children and adolescents

- Growth disturbance due to insufficient secretion of growth hormone (GH).

- Growth disturbance associated with Turner syndrome.

- Growth disturbance associated with chronic renal insufficiency.

- Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children/adolescents born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviation (SD), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by 4 years of age or later.

- Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.

Adults

- Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic

1. Name Of The Medicinal Product

Oruvail 150

2. Qualitative And Quantitative Composition

Ketoprofen 150mg

3. Pharmaceutical Form

Controlled release capsules

4. Clinical Particulars

4.1 Therapeutic Indications

Oruvail is recommended in the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute articular and peri-articular disorders, (bursitis, capsulitis, synovitis, tendinitis), cervical spondylitis, low back pain (strain, lumbago, sciatica, fibrositis), painful musculo-skeletal conditions, acute gout, dysmenorrhoea and control of pain and inflammation following orthopaedic surgery.

Oruvail reduces joint pain and inflammation and facilitates increase in mobility and functional independence. As with other non-steroidal anti-inflammatory agents, it does not cure the underlying disease.

4.2 Posology And Method Of Administration

Adults: 100 - 200mg once daily, depending on patient weight and on severity of symptoms.

The maximum daily dose is 200mg. The balance of risks and benefits should be carefully considered before commencing treatment with 200mg daily, and higher doses are not recommended (see also section 4.4).

Elderly: The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.

Paediatric dosage not established.

Oruvail capsules are for oral administration. To be taken preferably with or after food.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration neces

1. Name Of The Medicinal Product

OCTAGAM

solution for infusion

2. Qualitative And Quantitative Composition

2.1 Active ingredients

Human normal immunoglobulin (IVIg)

2.2 Quantitative composition:

1 ml solution contains:

Protein 100 mg
of which  
IgA
IgM

Distribution of IgG subclasses:

IgG1 ca. 60%
IgG2 ca. 32%
IgG3 ca. 7%
IgG4 ca. 1%

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Solution for infusion

The liquid preparation is clear to slightly opalescent and colourless to slightly yellow. The pH of the liquid preparation is 4.5 – 5.0, the osmolality is

4. Clinical Particulars

4.1 Therapeutic Indications

Replacement therapy in:

• Primary immunodeficiency syndrom

ONDEMET 2mg/ml Injection (Ondansetron 2mg/ml Solution for Injection and Infusion)

Read all of this leaflet carefully before you start using this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, please ask your doctor or pharmacist.
  • This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.

In this leaflet:

  • 1. What Ondemet Injection is and what it is used for
  • 2. Before you receive Ondemet Injection
  • 3. How Ondemet Injection will be given
  • 4. Possible side effects
  • 5. Storing Ondemet Injection

The name of this medicine is Ondemet 2mg/ml Injection (referred to as Ondemet Injection throughout this leaflet).

Marketing Authorisation Holder:

Beacon Pharmaceuticals Ltd.
The Regent
The Broadway
Crowborough
East Sussex
TN6 1DA
UK

Manufacturer:

This medicine is manufacture

1. Name Of The Medicinal Product

Osmanil 25 micrograms/h transdermal patch

2. Qualitative And Quantitative Composition

Each patch releases 25 micrograms fentanyl per hour. Each patch of 7.5 cm2 contains 4.125 mg fentanyl.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Transdermal patch

Transparent and colourless patch with blue imprint on the backing foil: “fentanyl 25 µg/h“.

4. Clinical Particulars

4.1 Therapeutic Indications

The product is indicated in severe chronic pain which can be adequately managed only with opioid analgesics.

4.2 Posology And Method Of Administration

The dosing is individual and based on the patient's opioid history and takes into account:

- the possible development of tolerance,

- the current general condition,

- the medical status of the patient and

- the degree of severity of the disorder.

The required fentanyl dosage is adjusted individually and should be assessed regularly after each administration.

Patients receiving opioid treatment for the first time

For initial dosing patches with a release rate of 12.5 micrograms/hour should be used. In very elderly or weak patients, it is not recommended to initiate an opioid treatment with Osmanil, due to their known susceptibility to opioid treatments. In these cases, it would be preferable to initiate a treatment with low doses of immediate release morphine and to prescribe Osmanil after determination of the optimal dosage.

Switching from other opioids

When changing over from oral or parenteral opioids to

1. Name Of The Medicinal Product

Ovitrelle 250 micrograms/0.5 ml solution for injection in a pre-filled syringe

2. Qualitative And Quantitative Composition

Each pre-filled syringe contains 250 micrograms choriogonadotropin alfa* (equivalent to approximately 6,500 IU) in 0.5 ml solution.

* recombinant human chorionic gonadotropin, r-hCG produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology

Excipients: 27.3 mg mannitol, 0.05 mg poloxamer 188, 0.1 mg L-methionine

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Solution for injection.

Clear, colourless solution.

The pH of the solution is 7.0 ± 0.3, its osmolarity 250-400 mOsm/l.

4. Clinical Particulars

4.1 Therapeutic Indications

Ovitrelle is indicated in the treatment of

• Adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth,

• Anovulatory or oligoovulatory women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligoovulatory women after stimulation of follicular growth.

4.2 Posology And Method Of Administration

Ovitrelle is intended for subcutaneous administration.

Treatment with Ovitrelle should be performed under the supervision of a physician experienced in the treatment of fertility problems.

Posology

The maximum dose is 250 micrograms. The following dose regimen should be used:

• Women undergoing superovulation pri

Opticrom Allergy 2% w/v Eye Drops

sodium cromoglicate

Is this leaflet hard to see or read?

Phone 01483 505515 for help

Read all of this leaflet carefully because it contains important information for you.

This medicine is available without prescription. However, you still need to use Opticrom Allergy carefully to get the best results from it.

  • Keep this leaflet. You may need to read it again
  • Ask your pharmacist if you need more information or advice
  • You must contact a doctor if your symptoms worsen or do not improve
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist

In this leaflet:

  • 1. What Opticrom Allergy is and what it is used for
  • 2. Before you use Opticrom Allergy
  • 3. How to use Opticrom Allergy
  • 4. Possible side effects
  • 5. How to store Opticrom Allergy
  • 6. Further information

What Opticrom Allergy is and what it is used for

Opticrom Allergy 2% w/v Eye Drops (called Opticrom Allergy in this leaflet) contain a medicine called sodium cromoglicate. This belongs to a group of medicines called anti-allergics.

It works by stopping the release of the natural substances in your eyes that can lead to an allergic reaction. Signs of an allergic reaction include itchy, watery, red or inflamed eyes and puffy eyelids.

Opticrom Allergy is used for the relief and treatment of eye allergies. These allergies can happen:

  • At any time of the year and is called ‘perennial allergic co

1. Name Of The Medicinal Product

ORENCIA

2. Qualitative And Quantitative Composition

Each vial contains 250 mg of abatacept.

Each ml contains 25 mg of abatacept, after reconstitution.

Abatacept is a fusion protein produced by recombinant DNA technology in Chinese hamster ovary cells.

Excipient: sodium: 0.375 mmol per vial

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Powder for concentrate for solution for infusion.

The powder is a white to off-white whole or fragmented cake.

4. Clinical Particulars

4.1 Therapeutic Indications

Rheumatoid arthritis

ORENCIA in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a TNF-alpha inhibitor.

A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.

Polyarticular juvenile idiopathic arthritis

ORENCIA in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. ORENCIA has not been studied in children under 6 years old.

4.2 Posology And Method Of Administration

Treatment should be initiated and supervised by specialist physi

1. Name Of The Medicinal Product

Oilatum Cream

2. Qualitative And Quantitative Composition

Contains Light Liquid Paraffin 6.0% w/w and White Soft Paraffin 15.0% w/w in a cream base.

Also contains cetostearyl alcohol and potassium sorbate.

For a full list of excipients, see Section 6.1.

3. Pharmaceutical Form

Cream.

A white to off-white cream.

4. Clinical Particulars

4.1 Therapeutic Indications

Oilatum Cream is indicated in the treatment of contact dermatitis, atopic eczema, senile pruritus, ichthyosis and related dry skin conditions.

4.2 Posology And Method Of Administration

Oilatum Cream may be used as often as required. Apply to the affected area and rub in well. It is especially effective after washing when the sebum content of the stratum corneum may be depleted resulting in excessive moisture loss.

Oilatum Cream is suitable for adults, children and the elderly.

4.3 Contraindications

Should not be used in patients with known hypersensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

Cetostearyl alcohol and potassium sorbate may cause local skin reactions (e.g. contact dermatitis).

Hospital users should follow local procedures and policies for using topical products on in-patients.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None

4.6 Pregnancy And Lactation

There are no restrictions on the use of Oilatum Cream during pregnancy or lactation.

4.7 Effects On Ability To Drive And Use Machines

None

4.8 Undesir

1. Name Of The Medicinal Product

Olanzapine Sandoz 5 mg Film-coated Tablets

2. Qualitative And Quantitative Composition

Each film-coated tablet contains 5 mg olanzapine.

Excipient: 148.22 mg lactose/film-coated tablet

For a full list of excipients, see section 6.1

3. Pharmaceutical Form

Film-coated tablet

White, round (8 mm diameter), with a breaking notch on one side.

The tablet can be divided into equal halves.

4. Clinical Particulars

4.1 Therapeutic Indications

Adults

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1).

4.2 Posology And Method Of Administration

Adults

Schizophrenia: The recommended starting dose for olanzapine is 10 mg/day.

Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1).

Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day. For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or